A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
MOMA Therapeutics
Astellas Pharma Inc
National Cancer Institute (NCI)
Eli Lilly and Company
Actuate Therapeutics Inc.
Novartis
Artios Pharma Ltd
University of California, San Francisco
Memorial Sloan Kettering Cancer Center